• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

    3.630 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5
    Open 3.630
    Bid (Size) 3.650 (1)
    Ask (Size) 3.890 (1)
    Prev. Close 3.630
    Today's Range 3.630 - 3.630
    52wk Range 2.500 - 11.11
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +4.61%
    +4.61%
    1 Month
    +31.05%
    +31.05%
    3 Month
    +15.97%
    +15.97%
    6 Month
    +17.10%
    +17.10%
    1 Year
    -63.70%
    -63.70%

    More News

    Read More
    VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
    Via InvestorPlace
    Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience: Q4 Earnings Insights
    Via Benzinga
    Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
    Via InvestorPlace
    Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today?
    Via Benzinga
    Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    US Stocks Edge Lower; Housing Starts Rise In October
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.